1 Result: Acelyrin
Acelyrin (SLRN), CRISPR Therapeutics (CRSP), Elevation Oncology (ELEV), STERIS (STE), Teleflex (TFX): Analyst Coverage and Potential Upside Revealed
May 30th, 2023
Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. Despite $SLRN closing. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login